Improving outcome assessment in pediatric vasculitis

No abstract is available for this paper.

• Publication year

  2014

• Venue

  International Journal of Clinical Rheumatology

• Publication date

  2014-02-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/IJR.14.2
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

  2013cited by this paper
• Performance of Birmingham Vasculitis Activity Score and disease extent index in childhood vasculitides.

  2012cited by this paper
• Airway manifestations in childhood granulomatosis with polyangiitis (Wegener's)

  2012cited by this paper
• Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS)

  2012cited by this paper
• The contrasting epidemiology of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis.

  2012cited by this paper
• Assessing the Performance of the Birmingham Vasculitis Activity Score at Diagnosis for Children with Antineutrophil Cytoplasmic Antibody-associated Vasculitis in A Registry for Childhood Vasculitis (ARChiVe)

  2012cited by this paper
• The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis

  2012cited by this paper
• Defining disease activity and damage in patients with small-vessel vasculitis

  2012cited by this paper
• The OMERACT Core Set of Outcome Measures for Use in Clinical Trials of ANCA-associated Vasculitis

  2011cited by this paper
• Development of Outcome Measures for Large-vessel Vasculitis for Use in Clinical Trials: Opportunities, Challenges, and Research Agenda

  2011cited by this paper
• Health‐related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody–associated vasculitis

  2011cited by this paper
• A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis.

  2011cited by this paper
• Patient‐reported outcome assessment in vasculitis may provide important data and a unique perspective

  2010cited by this paper
• Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

  2010cited by this paper
• EULAR/PRINTO/PRES criteria for Henoch–Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria

  2010cited by this paper
• Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index

  2010cited by this paper
• Endothelial injury and repair in systemic vasculitis of the young.

  2010cited by this paper
• EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation

  2010cited by this paper
• Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis

  2010cited by this paper
• Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic AntibodyAssociated Vasculitis

  2009cited by this paper
• Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index.

  2009cited by this paper
• Progress Towards a Core Set of Outcome Measures in Small-vessel Vasculitis. Report from OMERACT 9

  2009cited by this paper
• Developing outcome measures for paediatric rheumatic diseases.

  2009cited by this paper
• Quantitative detection of circulating endothelial cells in vasculitis: comparison of flow cytometry and immunomagnetic bead extraction

  2008cited by this paper
• Validation of the Childhood Health Assessment Questionnaire in active juvenile systemic lupus erythematosus.

  2008cited by this paper
• The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study.

  2008cited by this paper
• Modification and validation of the Birmingham Vasculitis Activity Score (version 3)

  2008cited by this paper
• Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis.

  2007cited by this paper
• Establishment of a pilot pediatric registry for chronic vasculitis is both essential and feasible: a Childhood Arthritis and Rheumatology Alliance (CARRA) survey.

  2007cited by this paper
• Multicenter validation of a new quality of life measure in pediatric lupus.

  2007cited by this paper
• Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden.

  2007cited by this paper
• The future of damage assessment in vasculitis.

  2007cited by this paper
• OMERACT: An international initiative to improve outcome measurement in rheumatology

  2007cited by this paper
• A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus.

  2006cited by this paper
• Development of comprehensive disease assessment in systemic vasculitis

  2006cited by this paper
• The Pediatric Rheumatology International Trials Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the definition of improvement.

  2006cited by this paper
• Etanercept plus standard therapy for Wegener's granulomatosis.

  2005cited by this paper
• EULAR/PReS endorsed consensus criteria* for the classification of childhood vasculitides

  2005cited by this paper
• Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.

  2005cited by this paper
• The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the disease activity core set.

  2005cited by this paper
• Endothelial and platelet microparticles in vasculitis of the young.

  2004cited by this paper
• Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies.

  2004cited by this paper
• Juvenile polyarteritis: results of a multicenter survey of 110 children.

  2004cited by this paper
• Validation of the Childhood Health Assessment Questionnaire in the Juvenile Idiopathic Myopathies

  2004cited by this paper
• International consensus on preliminary definitions of improvement in adult and juvenile myositis.

  2004cited by this paper
• A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.

  2003cited by this paper
• Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis.

  2003cited by this paper
• Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence.

  2003cited by this paper
• The PedsQL in pediatric rheumatology: reliability, validity, and responsiveness of the Pediatric Quality of Life Inventory Generic Core Scales and Rheumatology Module.

  2002cited by this paper
• Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins.

  2002cited by this paper
• Discordance between proxy-reported and observed assessment of functional ability of children with juvenile idiopathic arthritis.

  2001cited by this paper
• Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology.

  2001cited by this paper
• Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group.

  1999cited by this paper
• Sensitivity of the Systemic Lupus Erythematosus Disease Activity Index, British Isles Lupus Assessment Group Index, and Systemic Lupus Activity Measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus.

  1999cited by this paper
• The OMERACT filter for Outcome Measures in Rheumatology.

  1998cited by this paper
• Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides.

  1997cited by this paper
• Preliminary definition of improvement in juvenile arthritis.

  1997cited by this paper
• Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. I. Physician, parent, and patient global assessments

  1997cited by this paper
• European therapeutic trials in ANCA‐associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials EUROPEAN COMMUNITY STUDY GROUP ON CLINICAL TRIALS IN SYSTEMIC VASCULITIS ECSYSVASTRIAL (BMHl‐Cr93‐1078)

  1995cited by this paper
• Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.

  1994cited by this paper
• Academic Editor: David Moher, Children’s Hospital of Eastern

  year unknowncited by this paper

• Métricas em reumatologia pediátrica

  2022cites this paper